Elotuzumab

EMPLICITI®

Overview

Elotuzumab is a drug used for the treatment of multiple myeloma. It is for use in patients who have received one to three prior medications and is intended to be used in combination with lenalidomide and dexamethasone. It is given as an injection into a vein through an IV.

SparkCures ID 37
Developed By Bristol Myers Squibb
Brand Name Empliciti®
Generic Name Elotuzumab
Additional Names HuLuc63
Treatment Classifications
Treatment Targets

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Untreated / Newly Diagnosed Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.

Verified
A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in...
CC-92480
View Trial

SparkCures Verified Accurate, up-to-date information. Learn more

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

Verified
A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previou...
SELINEXOR
View Trial
Verified
FT538 in Subjects With Advanced Hematologic Malignancies
FT538
View Trial
Verified
A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in...
CC-92480
View Trial

SparkCures Verified Accurate, up-to-date information. Learn more

Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
View Trial
A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Mul...
IBERDOMIDE (CC-220)
View Trial
Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Verified
A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previou...
SELINEXOR
View Trial
Verified
Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT
MY CHECKPOINT
View Trial
Verified
FT538 in Subjects With Advanced Hematologic Malignancies
FT538
View Trial
Verified
A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in...
CC-92480
View Trial

SparkCures Verified Accurate, up-to-date information. Learn more

Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
View Trial
Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
View Trial
A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Mul...
IBERDOMIDE (CC-220)
View Trial
Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Resources

There are no resources, links or videos to display for this treatment.